Atopic dermatitis: emerging therapies.

Atopic dermatitis: emerging therapies. Semin Cutan Med Surg. 2017 Sep;36(3):124-130 Authors: Simpson E, Udkoff J, Borok J, Tom W, Beck L, Eichenfield LF Abstract Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis. PMID: 28895959 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28895959?dopt=Abstract

Source: Seminars in Cutaneous Medicine and Surgery - September 13, 2017 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research

More News: Dermatitis | Dermatology | Food and Drug Administration (FDA) | Skin